Related Experiment Videos
MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA
Zoran Z Zdraveski1, Jill A Mello, Christine K Farinelli
1Department of Chemistry and Division of Bioengineering and Environmental Health, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
The Journal of Biological Chemistry
|November 14, 2001
Summary
Mismatch repair deficiency causes resistance to cisplatin but not oxaliplatin. MutS protein binds cisplatin-damaged DNA more strongly than oxaliplatin-damaged DNA, explaining differential cellular responses.
Area of Science:
- Molecular Biology
- Genetics
- Cancer Research
Background:
- Mismatch repair (MMR) deficiency confers resistance to DNA-damaging agents like cisplatin, limiting its therapeutic efficacy.
- Cisplatin analogs, such as oxaliplatin, with diamminocyclohexane (DACH) ligands, bypass MMR-mediated resistance, offering alternative treatment options.
Purpose of the Study:
- To investigate the molecular mechanisms underlying differential cellular responses to cisplatin and DACH platinum analogs.
- To compare the binding interactions of the Escherichia coli mismatch repair protein MutS with DNA containing cisplatin versus DACH adducts.
Main Methods:
- Purified E. coli MutS protein was used to assess binding affinity to DNA modified with cisplatin or DACH adducts.
- Cytotoxicity assays were performed on various E. coli mutants (methylation-deficient and recombination-deficient) treated with cisplatin and DACH compounds.
Main Results:
- MutS exhibited a 2-fold higher affinity for cisplatin-modified DNA compared to DACH-modified DNA.
- ADP enhanced MutS binding to cisplatin-damaged DNA but not to DACH- or EN-adducted DNA.
- Methylation-deficient E. coli mutants showed 2-fold greater sensitivity to cisplatin than DACH compounds.
- Recombination-deficient mutants were highly sensitive to both platinum analogs, indicating they act as significant replication blocks.
Conclusions:
- Differential binding affinity of MutS to platinum-adducted DNA may explain the distinct cellular responses observed between cisplatin and oxaliplatin.
- Both cisplatin and DACH adducts function as potent replication blocks, with MMR status influencing sensitivity.
- Understanding these molecular interactions can guide the development of more effective platinum-based anticancer therapies.